Streetbeat News

Products Services

TSLA

XPEV

Chinese EV maker Xpeng Inc. (NYSE:XPEV) offered Tesla CEO Elon Musk a test drive of its advanced driver assistance system, XNGP, after Xpeng CEO He Xiaopeng tested Tesla's full self-driving (FSD) technology in the U.S. Musk acknowledged the competitiveness of Chinese automakers. The exchange highlights the ongoing competition and collaboration in autonomous driving technology between the two companies.

Portfolio Pulse from Anan Ashraf

June 21, 2024 | 12:03 pm

LXRX

Lexicon Pharmaceuticals has resubmitted its New Drug Application (NDA) for Sotagliflozin, intended as an adjunct to insulin therapy for glycemic control in Type 1 diabetes and chronic kidney disease. The company expects a six-month review period and a potential early 2025 launch.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 12:02 pm

ITRM

Iterum Therapeutics announced that the FDA will review its New Drug Application for oral sulopenem etzadroxil/probenecid for uncomplicated UTIs in an advisory committee meeting on September 9, 2024. The discussion will focus on antimicrobial stewardship and the target patient population.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 12:02 pm

AVTR

Avantor has appointed Corey Walker as the President of Laboratory Solutions. Corey will report directly to CEO Michael Stubblefield.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 11:49 am

AXSUSD

ETHUSD

SOLUSD

A Hong Kong court convicted Mingtung Wong for providing unlicensed investment advice in a Telegram group. Wong, a licensed representative with the Hong Kong SFC, managed a subscription-based group beyond his professional scope, leading to a HKD 10,000 fine. Separately, Ethereum co-founder Vitalik Buterin criticized celebrity-backed meme coins, urging the crypto community to focus on projects with lasting value.

Portfolio Pulse from Murtuza Merchant

June 21, 2024 | 11:40 am

PFE

SRPT

The FDA has approved the expanded use of Sarepta Therapeutics' (NASDAQ:SRPT) gene therapy Elevidys for Duchenne muscular dystrophy (DMD) to include both ambulatory and non-ambulatory patients aged 4 and above. Sarepta will conduct a confirmatory trial for non-ambulatory patients. The news follows disappointing results from Pfizer's (NYSE:PFE) Phase 3 study for a similar treatment.

Portfolio Pulse from Vandana Singh

June 21, 2024 | 11:39 am

KRKR

36Kr Holdings has partnered with SenseTime to integrate advanced AI technologies into its media content production, aiming to enhance efficiency and reduce costs. This collaboration will enable 36Kr to offer innovative AI-driven products and expand its customer base, boosting its commercialization capabilities.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 11:34 am

SRPT

Sarepeta Therapeutics shares are trading higher following FDA approval for an expanded indication of ELEVIDYS to treat Duchenne muscular dystrophy in individuals aged 4 and older with a confirmed DMD gene mutation. Multiple firms have also raised their price targets for the stock.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 11:32 am

GBTC

GS

IBIT

Standard Chartered is launching a Bitcoin and Ethereum trading desk, positioning itself as one of the first global banks to enter spot cryptocurrency trading. This move comes amid significant outflows from Bitcoin spot ETFs, with Grayscale experiencing substantial outflows and BlackRock seeing modest inflows.

Portfolio Pulse from Murtuza Merchant

June 21, 2024 | 11:25 am

VERI

Veritone has been selected by World Horse Racing as its exclusive digital asset management provider. This partnership is expected to enhance Veritone's market position in the digital asset management space.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 11:22 am